Incorporated less than a year ago, Breathonix is attempting to develop a better way to diagnose lung cancer compared to the current methods. In particular, it is building a software that can identify biomarkers from a patient’s exhaled breath that correlate with the lung disease.
SINGAPORE (Feb 21): At the SLINGSHOT 2019 start-up competition that took place during the Singapore FinTech Festival late last year, Breathonix was declared as one of two sector winners for the HealthTech, BioTech and MedTech category. The company beat more than 2,000 other participating start-ups worldwide to bag one of the 12 $50,000 Startup SG grants.
“We are very lucky to be [a] winner,” Du Fang, co-founder and chief operating officer of Breathonix, tells The Edge Singapore in a recent interview. “We didn’t expect [to win].”
